{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-005068","form_type":"8-K","ticker":"GDRX","cik":"0001809519","company_name":"GoodRx Holdings, Inc.","filed_at":"2023-02-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.682315+00:00","generated_at":"2026-06-18T22:33:00.297873+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"GoodRx Q4 revenue $184.1M beats guidance; Adjusted EBITDA margin 26.9% exceeds expectations","bullets":["Q4 revenue $184.1M, above guidance; net loss $2.01M (includes $29.4M stock-based comp).","Adjusted EBITDA $49.6M (26.9% margin), exceeding guidance; Adjusted Net Income $27.4M (14.9% margin).","Full year 2022 revenue $766.6M; Adjusted EBITDA $213.5M (27.8% margin).","Subscription offerings grew 42% YoY; over 7M consumers of prescription-related offerings.","Co-CEO cites strong subscription growth and efficiency improvements; 900K prescribers active."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-005068","json":"https://secwatch.observer/filing/0000950170-23-005068.json","markdown":"https://secwatch.observer/filing/0000950170-23-005068.md","text":"https://secwatch.observer/filing/0000950170-23-005068.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1809519/000095017023005068/0000950170-23-005068-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1809519/000095017023005068/gdrx-20230228.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T22:33:00.297873+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"99627a5952b20aaafd7368ab7c5def338646e598","claim":"GoodRx Holdings, Inc. reported Full Year 2022 results: revenue $766.6 million, net income $32.8 1 million.","evidence_excerpt":"Full Year 2022 Highlights • Total revenue of $766.6 million • Net loss of $32.8 1 million; Net loss margin of 4.3%","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1809519/000095017023005068/0000950170-23-005068-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"Full Year 2022"},{"label":"Revenue","value":"$766.6 million"},{"label":"Net income","value":"$32.8 1 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"c09a6ae2c425a9192da7fdef2c316a16d8e5e46e","claim":"GoodRx Holdings, Inc. reported Fourth Quarter 2022 results: revenue $184.1 million, net income $2.0 1 million.","evidence_excerpt":"Fourth Quarter 2022 Highlights • Total revenue of $184.1 million, exceeding previously announced guidance • Net loss of $2.0 1 million; Net loss margin of 1.1%","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1809519/000095017023005068/0000950170-23-005068-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"Fourth Quarter 2022"},{"label":"Revenue","value":"$184.1 million"},{"label":"Net income","value":"$2.0 1 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}